Headquartered in Eagan, MN Fiscal year ends December NYSE: SOLV solventum.com
Solventum is a healthcare company spun off from 3M. It develops products at the intersection of health, material and data science, and operates through three reportable segments.
- **MedSurg** includes two businesses:
- Advanced Wound Care: negative pressure wound therapy (V.A.C. Therapy), advanced wound dressings, advanced skin care and synthetic tissue matrices, including Restrata from the December 2025 acquisition of Acera Surgical.
- Infection Prevention and Surgical Solutions: IV site management, sterilization assurance, temperature management (Bair Hugger), surgical supplies, medical tapes and wraps, stethoscopes, medical electrodes and medical technologies OEM.
- **Dental Solutions** offers dental and orthodontic products, including brackets, aligners, restorative cements and bonding agents (e.g., Filtek), covering preventive care, direct and indirect restoration, and orthodontics.
- **Health Information Systems** provides software for computer-assisted physician documentation, direct-to-bill and coding automation, classification methodologies, speech recognition and data visualization. Solventum is reviewing strategic alternatives for this business, including a planned separation.
Outside its segments, the company retains a drinking water filtration business and supply agreements with 3M. It sold its Purification and Filtration business in September 2025.
Solventum is in the late stages of becoming a standalone company. It has exited about 90% of its transition service agreements with 3M and has completed its ERP system cutovers. Updated
The ERP cutover that dragged 630 basis points off organic sales is now done, and management used the clearing to raise full-year adjusted EPS guidance to $7.20 to $7.30. The separation from 3M is more than 90% complete.
Nelson Peltz just made a healthcare technology spinoff his largest institutional bet, and the combination of a dirt-cheap valuation, an activist legend, and a company still sorting out its own identity creates…
Chris MacDonald Solventum is a healthcare company spun off from 3M. It develops products at the intersection of health, material and data science, and operates through three reportable segments. - **MedSurg** includes two businesses: - Advanced Wound Care: negative pressure wound therapy (V.A.C.
24/7 Wall St.'s 12-month price target for SOLV is $110.33, rated Buy. The Wall Street consensus target is $98.38. SOLV price prediction →